Symptomatic Patients With Myelofibrosis Treated Post-JAK Inhibition
This roundtable series explores options for anemic patients with myelofibrosis after they have received a JAK inhibitor, as discussed by key opinion leaders and participants at virtual live events.
Trials Support Use of Momelotinib After JAK Inhibition for Anemic MF
November 21st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed data from the SIMPLIFY-2 and MOMENTUM trials of momelotinib for patients with myelofibrosis. This is the second of 2 articles based on this event.
Importance of Early Start to Therapy and SCT Referral in Myelofibrosis
December 19th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed approaches to starting JAK inhibitor therapy for a patient with myelofibrosis and when to refer for stem cell transplant. This is the first of 2 articles based on this event.
Transfusion Independence With Momelotinib Impacts OS in Myelofibrosis
January 11th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed dosing of JAK inhibitors therapy and how the survival data for ruxolitinib compares with that of momelotinib. This is the second of 2 articles based on this event.
